CeriBell, Inc. (NASDAQ:CBLL) Receives $22.20 Average Target Price from Analysts

CeriBell, Inc. (NASDAQ:CBLL) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $22.20.

CBLL has been the topic of a number of recent analyst reports. Canaccord Genuity Group decreased their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th.

Insiders Place Their Bets

In other news, Director William W. Burke sold 2,207 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total transaction of $43,786.88. Following the completion of the transaction, the director owned 23,022 shares of the company’s stock, valued at approximately $456,756.48. The trade was a 8.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Raymond Woo sold 1,966 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $18.00, for a total value of $35,388.00. Following the sale, the chief technology officer owned 195,682 shares of the company’s stock, valued at approximately $3,522,276. This represents a 0.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 300,685 shares of company stock valued at $5,935,326 over the last three months. 17.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new stake in shares of CeriBell in the 1st quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd increased its position in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CeriBell in the 3rd quarter valued at approximately $33,000. CWM LLC boosted its position in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter.

CeriBell Stock Performance

NASDAQ CBLL opened at $18.29 on Thursday. The firm has a 50-day moving average price of $18.52 and a two-hundred day moving average price of $19.14. CeriBell has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a market capitalization of $693.92 million, a P/E ratio of -11.22 and a beta of 0.81. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. Analysts anticipate that CeriBell will post -1.69 earnings per share for the current year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.